玻璃体内注射bevacizumab治疗新生血管性年龄相关性黄斑变性疗效评价及影响疗效的相关因素分析-眼科学专业论文 word格式.docxVIP

的差异，玻璃体内注射 Bevacizumab 治疗新生血管性 AMD 在中国人群中的疗效还不得而知。为了进一步完善对玻璃体内注射 Bevacizumab 治疗新生血管性 AMD 的 疗效评估，本研究通过临床回顾性研究探讨评价玻璃体内注射 Bevacizumab 治疗新 生血管性 AMD 的安全性和疗效，分析玻璃体内注射 Bevacizumab 治疗新生血管性 AMD 疗效差异的原因。1对象和方法1.1 对象2008 年 3 月至 2009 年 8 月在上海交通大学附属第一人民医院眼科就诊的新生 血管性 AMD 患者，眼科门诊经眼底检查、光学相干断层扫描（optical coherence tomography，OCT）、眼底荧光素血管造影（fluorescein fundus angiograph，FFA）、 吲哚菁绿血管造影（indocyanine green angiography，ICGA）确诊的连续病例 53 例 53 眼，其中男 33 例，女 20 例，年龄 47-85 岁，平均（68.8±10.2）岁。本项研 究经过北大人民医院中心伦理委员会讨论批准，并在上海交通大学附属第一人民医 院伦理委员会备案批准实施，所有患者签署有 Bevacizumab 知情同意书及注射手术 同意书。1.2 纳入、排除标准1.2.1纳入标准（1） 经眼底检查、OCT 和 FFA 确诊为新生血管性 AMD 的患者。（2） 具有活动期病变：1）色素上皮或者神经上皮脱离，视网膜内或视网膜下出血； 2）OCT 显示视网膜增厚，视网膜内、视网膜色素上皮下或神经上皮下有液 体。（3） 年龄大于 45 岁。（4） 自首次注射开始，随访时间不少于 12 个月。（5） 被告知本研究的各相关事宜，征得知情同意并签署知情同意书。PrefaceThe main cause of the visual impairment of European and American elderly people is age-related macular degeneration (AMD). AMD is also considered the irreversible blind cause for people who are over 50 years old.1, 2 It was reported3 in the literature in 2004 that there were more than 8 million AMD patients. Three world famous researches of epidemiology showed that the morbidity of AMD was 1.63% for white people over 55 years old. For those between 65 to 75 years old, the number turned into 16%, while the number boomed to 36.8% for people over 75 years old.4 Though the results of domestic surveys vary on the epidemiology of AMD in different periods and different regions, AMD appears an important public health problem. In 1987, it was reported in the literature that the prevalence of AMD was 10.6% in Chinese population.5 In 1998, the survey6 carried out by He Guangming showed that the morbidity of AMD arrived nearly 8.4% in a county of Guangdong province. In 2005, it was reported by Zou Haidong7 that the morbidity of AMD was about 15.5% in Cao Jiadu Street in Jingan district of Shanghai. In the same year, a survey about the morbidity of AMD in a village of Shan Xi province showed that the morbidity of AMD in peopl